◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksT › TRLV

Trulieve Cannabis Corp. (TRLV) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · DATA UPDATED 2026-09-06

Trulieve Cannabis Corp. (TRLV) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in Tallahassee, United States with about 5,000 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, TRLV reported $1.2B in revenue and ($116M) in net income.

Trulieve Cannabis Corp. operates as a cannabis retailer in the United States. The company cultivates, processes, and manufactures cannabis products and distributes its products to its dispensaries, as well as through home delivery.

Interactive charts & full statements → Open the TRLV valuation workbench →

TRLV Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-31
Total Revenue$1.1B$1.2B$1.2B$1.1B$1.2B
Gross Profit$677M$711M$716M$589M$689M
Gross Margin %59.5%60.2%60.3%52.1%56.6%
Operating Income (EBIT)($274M)$148M$92M$93M$126M
Operating Margin %-24.1%12.6%7.8%8.2%10.3%
Net Income($473M)($116M)($155M)($527M)($246M)
Net Margin %-41.6%-9.8%-13.1%-46.7%-20.2%
EBITDA($138M)$328M
Earnings Per Share (EPS)$-2.46$-0.61$-0.81$-2.83$-1.32
Shares Outstanding (M)193M191M191M186M186M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TRLV Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-31
Total Revenue$271M$287M$293M$288M$302M$298M
Gross Profit$162M$170M$175M$170M$183M$183M
Gross Margin %59.9%59.3%59.8%58.9%60.6%61.5%
Operating Income (EBIT)($371M)$35M$19M$41M$52M$35M
Operating Margin %-136.8%12.4%6.6%14.4%17.3%11.8%
Net Income($406M)$2M($43M)($27M)($14M)($33M)
Net Margin %-149.9%0.8%-14.6%-9.3%-4.6%-11.0%
EBITDA($371M)$82M$61M$89M$98M
Earnings Per Share (EPS)$-2.11$0.01$-0.22$-0.14$-0.07$-0.17
Shares Outstanding (M)193M198M192M191M191M191M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TRLV Free Cash Flow History

Cash flowTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-31
Cash from Operations (CFO)$245M$273M$271M$202M$23M
Capital Expenditures (CapEx)$58M$61M$148M$51M$194M
Free Cash Flow (FCF)$187M$212M$124M$151M($171M)
FCF Margin %16.4%18.0%10.4%13.4%-14.0%
Dividends Paid$0M$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TRLV Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-31
Cash from Operations (CFO)$53M$56M$59M$77M$86M$51M
Capital Expenditures (CapEx)$21M$13M$7M$17M$16M$21M
Free Cash Flow (FCF)$32M$42M$52M$60M$69M$30M
FCF Margin %11.8%14.7%17.8%20.9%23.0%10.2%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TRLV Balance Sheet History

Balance sheet2026-06-302025-12-312024-12-312023-12-312022-12-31
Total Assets$2.1B$2.7B$2.9B$2.7B$3.4B
Cash & Cash Equivalents$325M$256M$239M$201M$207M
Total Liabilities$1.3B$1.6B$1.6B$1.3B$1.5B
Total Debt (Short + Long-Term)$311M$258M$477M$479M$636M
Total Shareholders' Equity$767M$1.2B$1.3B$1.4B$1.9B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TRLV viewer.

Other Companies in DRUG MANUFACTURERS - SPECIALTY & GENERIC

← TRLTAll “T” companiesTRLX →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.